Proportion of participants in whose eyes SEIs had developed within 30 days of treatment initiation (lower is favored) · epidemic keratoconjunctivitis
It is very uncertain whether any intervention changes proportion of participants in whose eyes SEIs had developed within… compared with artificial tears or saline (very low certainty).
1 finding from 1 review
Proportion of participants in whose eyes SEI had disappeared within 21 days of treatment (higher is favored) · epidemic keratoconjunctivitis
It is very uncertain whether any intervention changes proportion of participants in whose eyes SEI had disappeared within… compared with artificial tears or saline (very low certainty).
1 finding from 1 review
Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who had evidence of adenoviral eradication within 14 days of treatment (higher is favored) · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 · children with cystic fibrosis
Dornase alfa may leads to higher mean relative percentage in FEV1 (L) at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Mean relative percentage in FVC (L) at 3 months · children with cystic fibrosis
Dornase alfa showed no clear difference in mean relative percentage in FVC (L) at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Mean relative percentage in quality of life score at 3 months · children with cystic fibrosis
Dornase alfa showed no clear difference in mean relative percentage in quality of life score at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Pulmonary exacerbations · children with cystic fibrosis
1 finding from 1 review
Manual removal of the placenta · management of retained placenta
Oxytocin solution may leads to lower manual removal of the placenta compared with saline solution (low certainty).
1 finding from 1 review
Maternal death · management of retained placenta
Oxytocin solution showed no clear difference in maternal mortality compared with saline solution (low certainty).
1 finding from 1 review
Severe PPH (≥ 1000 mL) · management of retained placenta
Oxytocin solution showed no clear difference in severe PPH (≥ 1000 mL) compared with saline solution (moderate certainty).
1 finding from 1 review
Blood transfusion · management of retained placenta
Oxytocin solution showed no clear difference in blood transfusion compared with saline solution (moderate certainty).
1 finding from 1 review
Addition of therapeutic uterotonics · management of retained placenta
Oxytocin solution showed no clear difference in addition of therapeutic uterotonics compared with saline solution (low certainty).
1 finding from 1 review
Need for antibiotics · management of retained placenta
Oxytocin solution showed no clear difference in need for treatment with antibiotics (infection) compared with saline solution (moderate certainty).
1 finding from 1 review
Maternal postpartum anaemia (haemoglobin 24–48 hours postpartum) · management of retained placenta
1 finding from 1 review
Time to recurrence · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in time to recurrence (absolute effect size estimates based on… compared with saline (low certainty).
1 finding from 1 review
Time to progression · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in time to progression (absolute effect size estimates based on… compared with saline (low certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade III–V adverse events compared with saline (low certainty).
1 finding from 1 review
Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes time to death from bladder cancer(absolute effect size estimates… compared with saline (very low certainty).
1 finding from 1 review